Feasibility and acceptability of the smart pillbox and medication label with differentiated care to support person-centered tuberculosis care among ASCENT trial participants - A multicountry study.

acceptability digital adherence technologies feasibility medication label smart pillbox tuberculosis

Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2024
Historique:
received: 25 10 2023
accepted: 15 01 2024
medline: 6 3 2024
pubmed: 6 3 2024
entrez: 6 3 2024
Statut: epublish

Résumé

Digital adherence technologies (DATs) can offer alternative approaches to support tuberculosis treatment medication adherence. Evidence on their feasibility and acceptability in high TB burden settings is limited. We conducted a cross-sectional survey among adults with drug-sensitive tuberculosis (DS-TB), participating in pragmatic cluster-randomized trials for the Adherence Support Coalition to End TB project in Ethiopia (PACTR202008776694999), the Philippines, South Africa and Tanzania (ISRCTN 17706019). From each country we selected 10 health facilities implementing the DAT intervention (smart pillbox or medication labels, with differentiated care support), ensuring inclusion of urban/rural and public/private facilities. Adults on DS-TB regimen using a DAT were randomly selected from each facility. Feasibility of the DATs was assessed using a standardized tool. Acceptability was measured using a 5-point Likert-scale, using the Capability, Opportunity, Motivation, Behavior (COM-B) model. Mean scores of Likert-scale responses within each COM-B category were estimated, adjusted for facility-level clustering. Data were summarized by country and DAT type. Participants using either the pillbox ( From client-perspective, pillboxes and medication labels with differentiated care support were feasible to implement and acceptable in variety of settings. However, implementation challenges related to network, phone access, stigma, additional costs to people with TB to use DATs need to be addressed.

Identifiants

pubmed: 38444445
doi: 10.3389/fpubh.2024.1327971
pmc: PMC10913790
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1327971

Informations de copyright

Copyright © 2024 Tadesse, Mganga, Dube, Alacapa, van Kalmthout, Letta, Mleoh, Garfin, Maraba, Charalambous, Foster, Jerene and Fielding.

Déclaration de conflit d'intérêts

TD, NM, and SC were employed by The Aurum Institute. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Amare W Tadesse (AW)

TB Centre, Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and Tropical Medicine (LSHTM), London, United Kingdom.

Andrew Mganga (A)

KNCV Tuberculosis Plus, Dar es Salaam, Tanzania.

Tanyaradzwa N Dube (TN)

Implementation Research Division, The Aurum Institute, Johannesburg, South Africa.

Jason Alacapa (J)

KNCV Tuberculosis Plus, Manila, Philippines.

Kristian van Kalmthout (K)

Evidence and Impact, KNCV Tuberculosis Plus, The Hague, Netherlands.

Taye Letta (T)

National Tuberculosis Control Program, Ethiopian Ministry of Health, Addis Ababa, Ethiopia.

Liberate Mleoh (L)

National Tuberculosis Control Program, Ministry of Health, Dodoma, Tanzania.

Anna M C Garfin (AMC)

National Tuberculosis Control Program, Department of Health, Manila, Philippines.

Noriah Maraba (N)

Implementation Research Division, The Aurum Institute, Johannesburg, South Africa.

Salome Charalambous (S)

Implementation Research Division, The Aurum Institute, Johannesburg, South Africa.
School of Public Health, University of Witwatersrand, Johannesburg, South Africa.

Nicola Foster (N)

TB Centre, Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and Tropical Medicine (LSHTM), London, United Kingdom.

Degu Jerene (D)

Evidence and Impact, KNCV Tuberculosis Plus, The Hague, Netherlands.

Katherine L Fielding (KL)

TB Centre, Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and Tropical Medicine (LSHTM), London, United Kingdom.
School of Public Health, University of Witwatersrand, Johannesburg, South Africa.

Classifications MeSH